Editorial illustration: three soft overlapping circles representing the three breast cancer subtypes, in cream, teal, navy, and ink with a delicate pink watercolor accent.
ER+ / PR+
~70% of cases
hormone receptors present
HER2+
~17% of cases
HER2 over-expressed
TNBC
~13% of cases
no receptors, no HER2
Breast cancer is three diseases, not one. Each subtype is treated differently.

Breast Cancer Treatment in Hyderabad

Breast cancer is the most commonly diagnosed cancer in Indian women, and the disease that benefits most from early, structured care. Dr. Madhav Danthala provides treatment planning, chemotherapy, targeted and hormonal therapy, and second opinions for breast cancer at Omega Hospitals, Gachibowli, and Peoples Polyclinic, Manikonda.

Subtype Shapes Treatment

Stage matters. Subtype matters more. Each of the three major breast cancer subtypes has a different first-line plan.

Breast cancer subtype distribution Horizontal stacked bar showing three major subtypes: ER+/PR+ at 70 percent treated with hormonal therapy first, HER2 positive at 17 percent treated with anti-HER2 plus chemotherapy, and triple negative at 13 percent treated with chemotherapy and immunotherapy. A SHARE OF NEW DIAGNOSES, INDIA 70% 17% 13% ER+ / PR+ 70% Hormonal therapy first. Often slower-growing. HER2+ 17% Anti-HER2 plus chemo. Targeted and effective. TNBC 13% Chemo plus immunotherapy. More aggressive subtype. Subtype is what shapes the first-line plan, not just stage.

When to See a Doctor

Most breast lumps are not cancer. The pattern that matters is when something is new, persistent, or changing. Four signs warrant evaluation.

Four warning signs for breast cancer A central watercolor circle representing the breast, with four annotated callouts pointing to a new lump, skin changes, nipple changes, and the external concept of family history. A new lump Persistent, firm, painless in breast or underarm. Skin changes Dimpling, redness, or peau d'orange texture. Nipple changes New inversion, discharge, or scaling around it. Family history Breast or ovarian cancer in a close relative under 50. Most signs are not cancer. Persistence is what warrants the visit.

Dr. Danthala's Approach

Breast cancer care is rarely one-size-fits-all. Three principles shape every consultation.

  1. Subtype-led planning

    Every plan begins with an honest understanding of the cancer's biology — receptor status, grade, Ki-67, and genomic risk where relevant — not stage alone.

  2. More than one path

    For early-stage disease, surgery-first and neoadjuvant-chemotherapy-first are both medically defensible in selected cases. The right path depends on the patient, not just the protocol.

  3. Clear, structured communication

    Every consult ends with a written summary of options, expected timelines, and the trade-offs each plan carries — so decisions are made calmly, not under pressure.

Frequently Asked Questions

At what age should I start breast cancer screening in India?

For average-risk women, mammographic screening typically begins at age 40 and continues every 1 to 2 years. If you have a family history of breast or ovarian cancer, especially before age 50, screening should start earlier — often a decade before the youngest affected relative's age at diagnosis.

Does every breast lump mean cancer?

No. The majority of breast lumps are benign — most often fibroadenomas, cysts, or fibrocystic changes. However, any new, persistent, or changing lump should be evaluated by a doctor with a clinical breast exam and imaging, particularly in women over 35.

What does ER positive, HER2 negative breast cancer mean?

ER positive means the cancer cells have receptors for the hormone estrogen and grow in response to it. HER2 negative means the cancer does not over-express the HER2 protein. ER+/HER2- is the most common subtype (around 70% of cases) and typically responds well to hormonal therapy alongside surgery and, when needed, chemotherapy.

Should I get a second opinion before starting treatment?

Yes — a second opinion is recommended, especially for newly diagnosed patients, for unusual or aggressive subtypes, or when recommendations seem unclear. In oncology, more than one defensible treatment path often exists. A second opinion confirms the plan or surfaces alternatives.

What is triple negative breast cancer (TNBC)?

Triple negative breast cancer is a subtype where the cancer cells do not have estrogen receptors, progesterone receptors, or HER2 over-expression. It tends to be more aggressive and is treated primarily with chemotherapy, often combined with immunotherapy. Newer regimens have significantly improved outcomes.

Consult Dr. Madhav Danthala

Whether for a first opinion, a second opinion, or treatment planning — book a focused consultation:

Book at Omega Hospitals

Mon-Sat, 10 AM to 4 PM. Gachibowli, Hyderabad.

Book at Omega

Book on Practo

Online booking — confirmation in minutes.

Book on Practo